Kodiak Sciences (NASDAQ:KOD – Get Rating) and Monte Rosa Therapeutics (NASDAQ:GLUE – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk and earnings.

Risk & Volatility

Kodiak Sciences has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500.

Earnings & Valuation

This table compares Kodiak Sciences and Monte Rosa Therapeutics' gross revenue, earnings per share and valuation.

Insider & Institutional Ownership

80.0% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 83.2% of Monte Rosa Therapeutics shares are owned by institutional investors. 42.6% of Kodiak Sciences shares are owned by company insiders. Comparatively, 3.5% of Monte Rosa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Kodiak Sciences and Monte Rosa Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and price targets for Kodiak Sciences and Monte Rosa Therapeutics, as provided by MarketBeat.

Kodiak Sciences currently has a consensus price target of $25.11, indicating a potential upside of 218.67%. Monte Rosa Therapeutics has a consensus price target of $18.60, indicating a potential upside of 149.66%. Given Kodiak Sciences' higher probable upside, research analysts clearly believe Kodiak Sciences is more favorable than Monte Rosa Therapeutics.

Summary

Monte Rosa Therapeutics beats Kodiak Sciences on 5 of the 8 factors compared between the two stocks.

About Kodiak Sciences

(Get Rating)

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

About Monte Rosa Therapeutics

(Get Rating)

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.